Interruptions in antiretroviral treatment increases risk of developing AIDS-related diseases

NewsGuard 100/100 Score

Interruptions in an HIV-positive person's antiretroviral treatment regimen can increase the risk of developing AIDS-related diseases and sometimes can be fatal, according to a study published Thursday in the New England Journal of Medicine, the Los Angeles Times reports.

The study -- known as Strategies for Management of Antiretroviral Therapy, or SMART -- was led by NIH and involved 5,472 HIV-positive people in 33 countries (Chong, Los Angeles Times, 11/30). The study began in January 2002 but was halted at the beginning of this year after preliminary results indicated that the mortality rates among the 2,720 participants who were in the treatment-interruption group were significantly higher, the San Francisco Chronicle reports. According to the Chronicle, participants in the treatment-interruption group stopped taking antiretrovirals when their CD4+ T cell counts were above 400 and restarted drug therapy when their T cell counts were below 250. The study found that those in the treatment-interruption group were 1.9 times more likely to die and had a substantially higher risk of becoming ill from AIDS-related diseases compared with those who did not interrupt their antiretroviral regimens (Russell, San Francisco Chronicle, 11/30). According to the study, 120 participants in the treatment-interruption group died or developed AIDS-related diseases, while 47 participants in the continuous-treatment group died during the study period (Los Angeles Times, 11/30). The study also found that 8% of all deaths were caused by AIDS-related diseases. The most common known cause of death among the participants was cancer, followed by cardiovascular disease and complications from substance abuse, the study found (San Francisco Chronicle, 1130). In addition, participants in the treatment-interruption group were 1.8 times more likely to develop serious kidney, heart or liver problems than the continuous-treatment group. Although researchers expected the rate of cardiovascular disease to be lower in the treatment-interruption group because heart problems are commonly reported side effects of antiretrovirals, the study found that 48% of participants in the treatment-interruption group developed cardiovascular problems, compared with 31% in the continuous-treatment group (Los Angeles Times, 11/30).

Donald Abrams, a researcher at the University of California-San Francisco, said it was difficult to explain why more people died in the treatment-interruption group because the actual number of deaths was low, the Chronicle reports. He added that one reason is that HIV or the inflammation it causes can negatively affect HIV-positive people in ways not fully understood (San Francisco Chronicle, 11/30). "This was a big surprise," James Neaton of the University of Minnesota said, adding, "Treatment may increase the risk" of heart, liver and kidney disease, "but the absence of treatment appears to increase the risk even more" (Emery, Reuters U.K., 11/29). Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases, said, "I think, for practical purposes, this is the end" of the stop-and-start antiretroviral treatment strategy (Los Angeles Times, 11/30).

Additional Articles
NEJM in its Nov. 30 issue ran other HIV/AIDS-related articles. Headlines appear below.

Kaiser Health NewsThis article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rethinking the germ theory: A balanced take on microbes and disease outcomes